Study purpose:

The phase 3 study is being done to evaluate the efficacy of NMRA-335140 compared to placebo on symptoms of depression participants with Major Depressive Disorder (MDD) following 6 weeks of treatment

What is the medication?

NMRA-335140

Overview:

Screening period: up to 28 days

Treatment Period: 6 weeks

Participants who complete the study will be given the opportunity to participate in 1 year extension study in which they will be guaranteed to receive active study medication

Follow up Period for those ending early or who decide not to participate in the extension study: 6 weeks

You May Qualify If:

You have been diagnosed with Major Depressive Disorder and are currently in a Major Depressive Episode

Qualified candidates may earn up to $100 per visit. Transportation assistance to those who enroll.